Arbutus Biopharma Corporation disclosed in a regulatory filing on July 16, 2026, that it has received its portion of the noncontingent settlement payment from Moderna, Inc., resolving the global patent infringement litigation over lipid nanoparticle (LNP) delivery technology. The filing also details the termination of a separate agreement with its licensee, Genevant Sciences GmbH, and outlines executive bonus arrangements linked to the litigation windfall.
Settlement Payment Received
The company confirmed that Moderna made the aggregate $950 million noncontingent lump sum payment to Arbutus and Genevant on July 8, 2026, as required under the March 2026 settlement agreement. Arbutus received approximately $178 million as its share, a figure that includes reimbursement of the company’s litigation costs. Moderna may still be obligated to make an additional contingent payment of up to $1.3 billion, depending on the outcome of a limited appeal Moderna filed under 28 U.S.C. §1498 and related litigation Arbutus and Genevant filed against the U.S. government in the Court of Federal Claims.
Termination of RSV Agreement
In a separate but related matter, Arbutus and Genevant terminated their March 2025 agreement concerning how proceeds tied to Moderna’s RSV vaccine, mRESVIA, would be allocated. Because the global settlement with Moderna did not specifically allocate any proceeds to mRESVIA-related infringing acts, the two parties agreed to terminate that agreement. Genevant will pay Arbutus a $1.0 million termination fee within ten business days.
Executive Bonus Arrangements
The board approved one-time cash bonuses for President and CEO Lindsay Androski and CFO Tuan Nguyen, directly tied to the litigation proceeds. Ms. Androski will receive 1.5% of the company’s share of the noncontingent settlement payment, payable by the end of July 2026. She is also eligible for 2.0% of any future proceeds from the Moderna §1498 appeal and U.S. government litigation, and 2.5% of any proceeds from the ongoing patent infringement litigation against Pfizer and BioNTech. Mr. Nguyen will receive a bonus equal to 0.25% of all proceeds received from the noncontingent settlement payment, including any dividend from Genevant’s parent company, with the board retaining discretion over any future bonus tied to remaining Moderna-related proceeds.
Capital Return to Shareholders
Arbutus also announced its intent to return up to approximately $230 million to shareholders in the third quarter of 2026 through share repurchases. The company stated that repurchases could take the form of a tender offer, including a modified Dutch auction, open market purchases, privately negotiated transactions, or accelerated share repurchases. The specific form remains subject to board approval, and any repurchase activity will not commence until after Arbutus receives an expected dividend from Genevant Parent, in which Arbutus holds an approximately 16% equity stake. The company cautioned that there is no assurance repurchases will occur on that timeline, or at all.
Ongoing Pfizer/BioNTech Litigation
Separately, Arbutus and Genevant have initiated three international patent infringement lawsuits against Pfizer and BioNTech, seeking to enforce the same LNP technology patents that were at issue in the Moderna dispute. The Androski bonus structure explicitly ties a portion of her compensation to any future proceeds from that litigation, signaling the board’s focus on monetizing the company’s intellectual property portfolio beyond the Moderna settlement.